Schedule I · misdemeanor possession
Pennsylvania lists psilocybin in Schedule I. A first simple-possession offense is a misdemeanor punishable by up to one year and a $5,000 fine.

PA legal and access quick reference
Reviewed on September 30, 2026 by iMD teamA concise, source-dated explanation of statewide law, regulated access, and the difference between state and local policy.
Laws and implementation can change quickly. This page is educational information, not legal advice.
Pennsylvania lists psilocybin in Schedule I. A first simple-possession offense is a misdemeanor punishable by up to one year and a $5,000 fine.
Pennsylvania has no statewide personal-use, retail, dispensary, or regulated psilocybin service program.
The University of Pennsylvania is developing psilocybin studies for opioid use disorder, supported by NIH/NIDA and Wellcome Leap funding. This research activity does not itself create a statewide public-access program.
The University of Pennsylvania Center for Studies of Addiction is developing the first psilocybin clinical research studies at Penn for opioid use disorder. The studies are designed to evaluate psilocybin as an add-on intervention for people already receiving methadone or buprenorphine treatment.
The research is supported by the National Institute on Drug Abuse and Wellcome Leap and involves collaboration among Penn Psychiatry, Drexel University and West Chester University of Pennsylvania. Penn investigators also reported related 2026 scientific work on neurocognitive mechanisms relevant to the planned psilocybin studies.
Separately, Penn researchers contributed to a 2026 living systematic review and meta-analysis of randomized controlled trials evaluating psilocybin treatment for depressive symptoms. These research developments expand Pennsylvania-based scientific activity around psilocybin without changing general statewide access rules.
For Allentown, Erie, Harrisburg, Philadelphia and Pittsburgh, this Pennsylvania page is the appropriate quick-reference starting point because no separate municipal action was retained as a distinct local-policy guide. Local rules can change, so verify current official records.
The statewide explanation above covers Allentown, Erie, Harrisburg, Philadelphia and Pittsburgh. A separate page appears below only where a documented municipal action adds material local context.
This page was checked against the controlling state statutes, enacted laws, agency records, and official bill histories listed below.
No. Pennsylvania lists psilocybin in Schedule I. A first simple-possession offense is a misdemeanor punishable by up to one year and a $5,000 fine. No statewide public-access program has been enacted.
No. Pennsylvania has not enacted a statewide psilocybin personal-use, retail, dispensary, or regulated service program.
No. A local enforcement-priority policy may affect municipal enforcement, but it does not legalize commercial sale, create statewide legality, or override federal law.
Yes. University of Pennsylvania researchers are developing NIH/NIDA- and Wellcome Leap-supported psilocybin studies for opioid use disorder, including work on brain and behavioral mechanisms. Penn researchers also contributed to a 2026 systematic review and meta-analysis of randomized psilocybin trials for depressive symptoms.
The product-site link provides product-format and business-policy information. It does not change the law described on this page or establish legal access in any jurisdiction.